Allergan targets filler-prone millennials with new Juvederm lip campaign

DDB Juvederm It for Allergan
Allergan extends its "Juvederm It" campaign with a specialty focus on lips, looking to attract millennials who tend to use fillers before neurotoxins such as Botox. (DDB New York)

It’s all about the lips in Allergan’s latest Juvederm campaign. In its first consumer effort focused on lip treatments, Allergan looks to especially target millennials with a natural—but individual—choice to create the lips they want.

Why now? Because millennials have flipped the script when it comes to facial aesthetics. Traditionally, neurotoxins have been the gateway to injectables with the Gen X generation, who then move on to fillers like Juvederm, said Colleen McKenna, Allergan's vice president of marketing for facial aesthetics. However, today’s 30-somethings are just as likely to start with a filler as a neurotoxin like Botox, an Allergan sibling product and market leader. And for millennials, fillers mean lips.

“They are jumping into this category with lip treatments. It’s really an opportunity for us to talk about lips and how you can get the look you want that’s natural and authentic to you,” McKenna said.

RELATED: Special Report: 2019 FiercePharma Marketing Awards winner in television: 'Juvederm It'

Featured in the new campaign are reality TV star Audrina Patridge along with a celebrity makeup artist Kelsey Deenihan, who will be doing media interviews and talking on social media about why they choose Juvederm for lips. The effort includes TV, with a custom version of the Juvederm It commercial already running, along with digital ads, social media and public relations.

In an additional campaign promotion, people can enter a contest online to win prizes, including a limited edition lipstick kit, which consists of three shades curated by Deenihan and created by SheSpoke custom makeup studio.

However, the focus on millennials doesn’t mean Gen X is completely left out. McKenna said the broader individual choice message applies to the older group as well who may, for instance, want a more youthful look for thinner lips. The Allergan campaign centers on both its Juvederm Ultra XC and Juvederm Volbella XC filler products.

RELATED: Allergan amps aesthetics advertising in bid to keep flagship Botox on top

While Allergan and AbbVie are still working out the final details in their $63 billion merger, the two have already announced they will carve out a separate Allergan Aesthetics global subsidiary. Current Allergan products Juvederm, Botox, Kybella and CoolSculpting, along with other aesthetics will be housed in the new business when the deal closes, expected by the end of the first quarter.,

Carrie Strom, Allergan's current senior VP of U.S. medical aesthetics, will lead Allergan Aesthetics, as well as take a senior VP role at AbbVie.

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.